SCG-211

N/A

Report date: 2026/03/19 16:53:30

Base Information

Drug NameSCG-211
Drug Alias Nameanti-CD3 bispecific T-cell engager (SCG Cell Therapy)SCG-201SCG-211
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSCG Cell Therapy Pte Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSCG Cell Therapy Pte Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A